PP
KPTI icon

PDT Partners’s Karyopharm Therapeutics KPTI Stock Holding History

PDT Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-682
Closed -$46K – 966
2022
Q2 		$46K Sell
682
-1,370
-67% -$126K ﹤0.01% 917
2022
Q1 		$227K Buy
+2,052
New +$256K 0.02% 791
2021
Q2 		– Sell
-4,735
Closed -$747K – 891
2021
Q1 		$747K Buy
+4,735
New +$998K 0.05% 418
2015
Q3 		– Sell
-1,908
Closed -$779K – 1424
2015
Q2 		$779K Buy
+1,908
New +$825K 0.02% 818

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

PDT Partners's KPTI Position: Q3 2022 in Review

PDT Partners sold out of Karyopharm Therapeutics (KPTI) in Q3 2022, closing a stake of 682 shares — an estimated $46K sold.

PDT Partners first reported a position in KPTI in Q2 2015 and held it in 4 quarters. The position peaked at $779K in Q2 2015. 147 funds tracked by Wall St. Rank hold KPTI as of Q3 2022.

  • PDT Partners reported no remaining Karyopharm Therapeutics position as of Q3 2022 after selling out during the quarter.
  • PDT Partners sold 682 Karyopharm Therapeutics shares in Q3 2022, an estimated $46K.
  • PDT Partners first reported a position in Karyopharm Therapeutics in Q2 2015 and held it in 4 quarters.
  • PDT Partners's Karyopharm Therapeutics position peaked at $779K in Q2 2015.
  • 147 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2022.

Based on PDT Partners's 13F filing for Q3 2022, filed 14 Nov 2022.